Supplementary Figure 3 from Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model

Pedram Kharaziha,Hendrik De Raeve, Charlotte Fristedt, Qiao Li,Astrid Gruber,Per Johnsson,Georgia Kokaraki, Maria Panzar, Edward Laane,Anders Österborg,Boris Zhivotovsky,Helena Jernberg-Wiklund,Dan Grandér, Fredrik Celsing,Magnus Björkholm,Karin Vanderkerken,Theocharis Panaretakis

crossref（2023）

引用 0|浏览6

暂无评分

摘要

PDF file - 36K, A, Quantitative analysis of Annexin V/PI positive murine 5T33MMvitro cells treated the indicated concentrations of sorafenib for 24h and 48h; B, Immunoblot analysis of the indicated proteins from the 5T33MMvitro cell line treated with 10 muM Sor for the indicated time points. C, Immunoblot analysis of the indicated proteins from murine 5T33MMvivo treated ex-vivo with 10 muM Sor for 24h

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Supplementary Figure 3 from Sorafenib Has Potent Antitumor Activity against Multiple Myeloma &lt;i&gt;In Vitro&lt;/i&gt;, &lt;i&gt;Ex Vivo&lt;/i&gt;, and &lt;i&gt;In Vivo&lt;/i&gt; in the 5T33MM Mouse Model

Supplementary Figure 3 from Sorafenib Has Potent Antitumor Activity against Multiple Myeloma <i>In Vitro</i>, <i>Ex Vivo</i>, and <i>In Vivo</i> in the 5T33MM Mouse Model